Guardant Health Showcases Precision Oncology at ASCO GI 2025
Guardant Health, Inc. (Nasdaq: GH), a prominent leader in precision oncology, is set to reveal important research outcomes related to cancer detection and treatment decisions at an esteemed conference. This highly anticipated event will take place during the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). The presentations will underline the innovative applications of Guardant's advanced oncology tools in various cancer care settings.
Key Research Highlights from ASCO GI 2025
The focus of Guardant Health's presentations will include critical studies examining the role of mutations in influencing treatment responses, particularly within colorectal and biliary tract cancers. Furthermore, findings will reinforce the significant advantages of utilizing blood-based screening methods in detecting colorectal, gastric, and esophageal cancers. Notably, a rapid oral presentation will spotlight the results of the phase II NEO trial, where Guardant Reveal played a key role in supporting organ preservation for patients with node-negative rectal cancer undergoing comprehensive neoadjuvant chemotherapy.
Impact of Precision Oncology Tools
Craig Eagle, MD, the Chief Medical Officer at Guardant Health, emphasizes the growing evidence for the relevance of precision oncology and liquid biopsies in accurately identifying gastrointestinal cancers. These tools are proving invaluable not only in guiding effective treatment choices but also in monitoring recurrence and assessing therapy response. The insights shared at ASCO GI will reflect the latest advancements by Guardant Health and its collaborators in these domains, which ultimately aim to enhance personalized cancer care and improve patient outcomes.
Overview of Presentations at ASCO GI 2025
Guardant Health will showcase a series of co-authored posters and presentations that exemplify the effectiveness of their precision oncology products. Among these are:
Guardant Reveal
Scheduled for January 25, 2025, from 9:15 to 10:00 am PST in Level 2, Ballroom, the focus will be on "Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II NEO trial (CCTG CO.28)." This rapid oral abstract will be part of Session C, with Abstract #20 featured.
Guardant360®
This presentation will include two significant retrospective studies on January 25, 2025, in Level 1, West Hall. One study will discuss the genomic landscape of anal squamous cell carcinoma using liquid biopsy, presented at 7:00 to 7:55 am PST, under Poster Session C, Abstract #8. The second will delve into the dynamics of metastatic colorectal cancer (CRC) in India, focusing on comprehensive circulating tumor DNA (ctDNA) next-generation sequencing, also presented under Poster Session C, Abstract #49.
GuardantINFORM™
On January 24, 2025, from 11:30 am to 1:00 pm PST, in Level 1, West Hall, Guardant Health will discuss "Real-world survival differences in advanced biliary tract cancer patients with ctDNA detected IDH1 mutations and FGFR2 fusions receiving first-line gemcitabine-cisplatin with and without immunotherapy." This presentation will be part of Poster Session B, featuring Abstract #548.
ShieldTM
Another focal point will be on January 25, 2025, at 7:00 to 7:55 am PST, in Level 1, West Hall, addressing the "Cost-effectiveness of blood-based colorectal cancer screening: A simulation model incorporating real-world longitudinal adherence," presented under Poster Session C, Abstract #93. Additionally, they will unveil a method for classifying colorectal cancer and gastric/esophageal cancer utilizing blood-based testing, also under Poster Session C, Abstract #52.
Future of Cancer Care with Guardant Health
Through their cutting-edge research and innovative testing solutions, Guardant Health strives to redefine cancer care. They focus on empowering patients and healthcare professionals by providing in-depth insights across all stages of cancer management. This includes early detection and cancer monitoring strategies to tailor treatment plans for those diagnosed with advanced cancer. The commitment of Guardant Health is to ensure they are at the forefront of advancements in precision oncology.
Frequently Asked Questions
What is the significance of Guardant Health's presentations at ASCO GI 2025?
The presentations highlight advancements in precision oncology and the crucial role of liquid biopsies in improving cancer detection, treatment decision-making, and patient outcomes.
When and where will Guardant Health's presentations take place?
Presentations are scheduled for January 24-25, 2025, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.
What topics are being covered in the presentations?
Key topics include the effectiveness of blood-based screening, genomic studies of cancers, and innovative decision-making tools for cancer treatment.
Who is presenting at the event?
Diverse research collaborators and experts, including Dr. Craig Eagle from Guardant Health, will present the findings and insights at ASCO GI 2025.
How does Guardant Health contribute to patient care?
Guardant Health enhances patient care through innovative testing solutions that generate critical insights for cancer detection, treatment selection, and monitoring.
